United States - English - NLM (National Library of Medicine)

genentech, inc. - saquinavir mesylate (unii: uhb9z3841a) (saquinavir - unii:l3je09kz2f) - saquinavir 200 mg - invirase in combination with ritonavir and other antiretroviral agents is indicated for the treatment of hiv-1 infection in adults (over the age of 16 years). the following points should be considered when initiating therapy with invirase/ritonavir: invirase/ritonavir is contraindicated in patients with congenital long qt syndrome, those with refractory hypokalemia or hypomagnesemia, and in combination with drugs that both increase saquinavir plasma concentrations and prolong the qt interval [see warnings and precautions (5.4) and clinical pharmacology (12.2)] . invirase/ritonavir is contraindicated in patients with complete atrioventricular (av) block without implanted pacemakers, or patients who are at high risk of complete av block [see warnings and precautions (5.3)] . invirase/ritonavir is contraindicated in patients with clinically significant hypersensitivity (e.g., anaphylactic reaction, stevens-johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients. invirase/ ritonavir is con

Israel - English - Ministry of Health

j-c health care ltd - bedaquiline as fumarate - tablets - bedaquiline as fumarate 100 mg - bedaquiline - sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (mdr-tb) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 100mg - film coated tablet - 100 mg - active: palbociclib 100mg excipient: colloidal silicon dioxide crospovidone opadry green 03k110010 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 125mg - film coated tablet - 125 mg - active: palbociclib 125mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - palbociclib 75mg - film coated tablet - 75 mg - active: palbociclib 75mg excipient: colloidal silicon dioxide crospovidone opadry purple 03k100008 magnesium stearate microcrystalline cellulose succinic acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. in pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (lhrh) agonist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - nirmatrelvir 150mg;  ;  ;  ; ritonavir 100mg - film coated tablet - active: nirmatrelvir 150mg       excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate microcrystalline cellulose opadry pink 05b140011 purified water sodium stearyl fumarate active: ritonavir 100mg - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid- 19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to covid-19 and are at increased risk of progression to hospitalisation or death.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. limitations of use: qualaquin is not approved for: qualaquin is contraindicated in patients with the following: risk summary prolonged experience with quinine in pregnant women over several decades, based on published prospective and retrospective observational studies, surveys, safety and efficacy studies, review articles, case reports and case series have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (see data) . in animal reproduction studies, administration of quinine by multiple routes of administration to pregnant rabbits, dogs, guinea pigs, rats, and monkeys during the period of organogenesis at doses of 0.25 to 2 times the maximum recommended human dose (mrhd) based on body su

United States - English - NLM (National Library of Medicine)

ar scientific inc. - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - diazepam 2mg - tablet - 2 mg - active: diazepam 2mg excipient: lactose magnesium stearate maize starch purified water - adults: short term (2-4 weeks) symptomatic treatment of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness. short term (2-4 weeks) treatment of conditions where anxiety may be a precipitating or aggravating factor e.g. tension headaches or migraine attack. symptomatic treatment of acute alcohol withdrawal. muscle spasm. as an adjunct to the control of muscle spasm in tetanus. may be useful in the management of cerebral spasticity in selected cases. as a adjunct to the management of some types of epilepsy, e.g. myoclonus. premedication. children: night terrors and somnambulism. may be useful in controlling tension and irritability in cerebral spasticity in selected cases. as an adjunct to the control of muscle spasm in tetanus. premedication.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - diazepam 5mg - tablet - 5 mg - active: diazepam 5mg excipient: lactose magnesium stearate maize starch purified water quinoline yellow - adults: short term (2-4 weeks) symptomatic treatment of anxiety that is severe, disabling or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness. short term (2-4 weeks) treatment of conditions where anxiety may be a precipitating or aggravating factor e.g. tension headaches or migraine attack. symptomatic treatment of acute alcohol withdrawal. muscle spasm. as an adjunct to the control of muscle spasm in tetanus. may be useful in the management of cerebral spasticity in selected cases. as a adjunct to the management of some types of epilepsy, e.g. myoclonus. premedication. children: night terrors and somnambulism. may be useful in controlling tension and irritability in cerebral spasticity in selected cases. as an adjunct to the control of muscle spasm in tetanus. premedication.